Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018
Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018
This Competitive Intelligence report analyzes the competitive field of CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators as of July 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage. The mainly selective, but also bispecific new molecular entities activate the immune checkpoints, including
The report includes a compilation of currently active projects in research and development of mostly recombinant antibodies activating immune checkpoints CD40, GITR, OX40, 4-1BB, CD27, ICOS & others. In addition, the report lists company-specific R&D pipelines of activators of immune checkpoints. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report analyzes the competitive field of CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators as of July 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage. The mainly selective, but also bispecific new molecular entities activate the immune checkpoints, including
- CD40 (TNFSFR5)
- GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
- OX40 (CD134; TNFSFR4)
- 4-1BB (CD137; TNFSFR9)
- CD27 (TNFSFR7)
- ICOS (Inducible Co-Stimulator)
The report includes a compilation of currently active projects in research and development of mostly recombinant antibodies activating immune checkpoints CD40, GITR, OX40, 4-1BB, CD27, ICOS & others. In addition, the report lists company-specific R&D pipelines of activators of immune checkpoints. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) CD40, GITR, OX40, 4-1BB, CD27, ICOS & OTHER IMMUNE CHECKPOINT ACTIVATORS
1a) CD40 Agonists
1b) GITR Agonists
1c) OX40 Agonists
1d) 4-1BB (CD137) Agonists
1e) CD27 Agonists1f) ICOS Agonists
1g) Other Immune Checkpoint Activators
2) CORPORATE IMMUNE CHECKPOINT ACTIVATOR R&D PIPELINES
1a) CD40 Agonists
1b) GITR Agonists
1c) OX40 Agonists
1d) 4-1BB (CD137) Agonists
1e) CD27 Agonists1f) ICOS Agonists
1g) Other Immune Checkpoint Activators
2) CORPORATE IMMUNE CHECKPOINT ACTIVATOR R&D PIPELINES
